Skip to main content
KRSA
NASDAQ Life Sciences

Korsana 10-Q: $456.2M Cash Funds Operations Into 2029 After Cyclerion Merger

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$30.56
Mkt Cap
$1.392B
52W Low
$7.186
52W High
$59.36
52W Position info
325% above low
Off High info
49% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

KRSA has more than doubled off its 52-week low of $7.186.

Summary

Korsana's first post-merger 10-Q shows a $46.4M third-quarter net loss and $456.2M of cash that management says funds operations into 2029, with the loss inflated by non-cash warrant-related stock compensation.


Key Events · Earnings and Guidance · KRSA

  • First Post-Merger Quarter Reported

    Q3 2026 net loss of $46.4M and nine-month net loss of $77.3M, the first results reflecting the September 8, 2026 reverse recapitalization with Cyclerion.

  • Cash Runway Extended Into 2029

    Cash and cash equivalents of $456.2M at September 30, 2026, up from $154.1M at December 31, 2025 after the $380.0M pre-closing private placement; management says this funds operating plans into 2029.

  • Loss Inflated by Non-Cash Warrant Charge

    R&D expense of $42.1M for the quarter included $12.7M of non-cash stock compensation for the 2026 Parasa Warrant Obligation; a $13.5M related-party warrant liability sits on the balance sheet.

  • Share Count and Overhang Detail

    45,541,358 common shares outstanding as of November 2, 2026, plus 5,361,846 pre-funded warrants at $0.0001 and 7,277,108 options at a $7.23 weighted-average exercise price.


Analysis · KRSA · Life Sciences

This is the first full set of financials since Korsana closed its reverse recapitalization with Cyclerion on September 8, 2026, so it offers the first look at the combined company's actual cost base. The quarter's $46.4M net loss is driven by $42.1M of R&D, and $12.7M of that quarter's R&D line is non-cash stock compensation tied to the 2026 Parasa Warrant Obligation rather than cash burn. Against that, $456.2M of cash and equivalents (up from $154.1M at year-end after the $380M pre-merger private placement) is stated to fund operations into 2029, which removes near-term financing risk for a company whose lead asset KRSA-028 is still preclinical. The offset is dilution already embedded in the share count: 45.5M shares outstanding versus 1.2M at December 31, 2025, plus 5.4M pre-funded warrants and 7.3M options. A special shareholder meeting on November 13, 2026 will vote on redomestication to the Cayman Islands.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KRSA was trading at $30.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.19 to $59.36. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KRSA - Latest Insights

KRSA
Nov 05, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.56
Real-time Price: $37.97 info
Change: +$7.41 (+24%) info
Market Cap: $1.669B info
KRSA
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $30.56
Real-time Price: $37.97 info
Change: +$7.41 (+24%) info
Market Cap: $1.669B info
KRSA
Oct 05, 2026, 4:14 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $30.72
Real-time Price: $37.97 info
Change: +$7.25 (+24%) info
Market Cap: $1.669B info